Objective: Advancing life expectancy with the increased prevalence of aortic valve degenerative disease brings the need for an aortic bioprosthesis with excellent haemodynamic performance and comparable durability. The Mitroflow bioprosthesis has been on the worldwide market, except in the United States, since 1982, while the current model (1991) has only recently gained regulatory approval in the latter country. This study was primarily performed to determine the durability of the current Mitroflow bioprosthesis. Methods: The contemporary Mitroflow bioprosthesis was implanted in 381 patients in three centres. The mean age was 76.4 years (range 53-91 years) and the mean followup period was 5.4 AE 3.4 years, a total of 2048.7 years of evaluation. The survival, at 10 years, was 39.9 AE 7.9% for 50-69 years, 27.0 AE 3.7% for 70-79 years and 16.6 AE 4.4% for !80 years ( p = 0.011). There was a trend ( p = 0.063) influencing survival for moderate-to-severe PPM. Of the independent predictors influencing survival -moderate-to-severe projected effective orifice area index (pEOAI) (Hazard Ratio (HR) 1.6, p = 0.0142) and left ventricular dysfunction (ejection fraction <35%) (HR 1.9, p = 0.0193) were included. The 10-year freedom from structural valve deterioration (SVD) at explant assessing the same age groups as survival was not different ( p = 0.081). The 10-year actual/actuarial freedom from SVD, at explant was for !60 years -94.4 AE 1.4% (85.2 AE 3.9%), for !65 years -94.2 AE 1.4% (85.0 AE 4.0%), for 61-70 years -97.4 AE 2.6% (95.7 AE 4.3%) and for >70 years -94.0 AE 1.5% (83.2 AE 4.6%). Conclusions: The Mitroflow external mounted, pericardial aortic bioprosthesis with documented excellent haemodynamics (especially for the small aortic root), demonstrates that prosthesis-patient mismatch in moderate and severe categories can essentially be eliminated, with durability performance comparable to other heterograft (porcine and pericardial) bioprostheses. #
Introduction
The Mitroflow aortic pericardial bioprosthesis has been available worldwide, except the United States, since 1982. The current model, introduced in 1991, was approved in the United States in 2007. The published literature has documented the performance of the initial model or a combination of the initial and current models [1] [2] [3] [4] [5] [6] [7] . This is the first assessment of the mid-term clinical performance of the current model of the Mitroflow aortic pericardial bioprosthesis.
There has been recent attention given to the haemodynamic performance of the prosthesis [8, 9] . These evaluations revealed that the prosthesis provides the opportunity for superior haemodynamics for the small aortic annulus ( 21 mm [9] . The objective of the study was to determine the mid-term durability and clinical outcomes of the Mitroflow aortic bioprosthesis and the predictors of mortality, inclusive of potential prosthesis-patient mismatch (PPM), with the bioprosthesis.
Materials and methods
This is a retrospective study from three prospectively maintained cardiac valve databases. The follow-up and data collection methods for each centre have been reported previously [3, 5, 10] . The patient population is presented in Table 1 . The patients in this study cohort were implanted with the prosthesis at the three participating centres from 1992 to 2003 [3, 5] , but primarily antiplatelet therapy in Vancouver [11] .
We calculated the potential PPM for each patient using reference effective orifice areas (EOAs) average, derived for each size of the Mitroflow valve [8, [12] [13] [14] [15] . The reference EOAs were indexed to the patient's BSA to calculate the projected EOA index (pEOAI) and classify patients into PPM categories [16] (Table 2) . Moderate-tosevere obesity was present in 15.7% (58). The two patients classified as severe PPM also had moderate or severe obesity.
The closing date for follow-up at the three centres was February to August 2007. The mean follow-up was 5.4 AE 3.4 years, with a total of 2048.7 years of evaluation, and the maximum follow-up was 14 years. At the close of follow-up, 24 patients were unaccounted for or reported lost, for a patient follow-up rate of 94%. The follow-up completeness based on duration of follow-up was 88.8% [17] .
Statistical methods
The 2008 and 1996 Society of Thoracic Surgeons (STS)/ American Association of Thoracic Surgeons (AATS)/European Association for Cardio-Thoracic Surgery (EACTS) guidelines [18, 19] were used for determination of valve-related complications and composites of complications. Linearised hazard rates for late events (>30 days) are detailed with standard errors and 95% confidence intervals. The KaplanMeier method was used to assess the time-related outcome of survival and freedom from valve-related complications and composites. Comparison of curves among patient groups (e.g., age, pEOAI) was performed with a log-rank test at the 0.05 level of significance. Cumulative incidence analysis by a modification of the Kaplan-Meier method was used to calculate the actual freedom from valve-related complications or composites of complications [20] . Multi-decrement analysis considered the combined freedom (%) from mortality, SVD and other explant, and the individual cumulative incidence (%) for mortality, SVD and other explant. A parametric Weibull analysis was used to illustrate the hazard function, or instantaneous risk, of explant from SVD occurring Preoperative variables were considered in risk modelling of overall mortality using Cox proportional hazards model.
Results
The valve-related events (early and late) for valve-related complications, composites of complications and mortality are summarised in Table 3 . The Kaplan-Meier freedoms from complications and composites of valve-related complications (actuarial) to 10 years are summarised in Table 4 .
Of the 20 early deaths (5.2%), there were 14 cardiac deaths, five non-cardiac deaths and one undetermined. There were no documented valve-related early deaths. Of the 228 late deaths, 35 were considered valve-related, 55 cardiac, 72 non-cardiac deaths and 66 were undetermined. Of the late valve-related deaths, 12 were classified as prosthetic valve endocarditis, 18 as thrombo-embolism and two as structural valve deterioration. The undetermined deaths are likely related to elderly patients dying at home or nursing institutions, since the mean age at implantation was 76.4 years. The autopsy rate was considered to be very low in this population.
The patient survival and cumulative hazard of mortality by age groups are detailed in Fig. 1 . The 10-year survival for the 50-69 age group was 39.9 AE 7.9%, for the 70-79 age group was 27.0 AE 3.7% and for !80 years was 16.6 AE 4.4% ( p = 0.011). The distribution of EOAI for the survival groupings revealed that moderate-to-severe EOAI was 11.4%, 12.8% and 11.4%, respectively.
The patient survival and cumulative hazard by pEOAI was marginal ( p = 0.063). The 10-year survival for absence of PPM was 28.8 AE 3.8%, for mild PPM was 26.9 AE 4.9% and for moderate and severe PPM combined was 12.9 AE 6.6%.
The multivariate predictors of mortality were determined by risk analysis. Among the independent predictive variables were age !80 years (HR 1.6; p = 0.0016), moderate-to-severe PPM (HR 1.6, p = 0.0142) and left ventricular ejection fraction (LVEF < 35%; HR 1.9, p = 0.0193). The others were: preoperative New York Heart Association (NYHA) (HR 1.3, p = 0.0144), coronary artery disease (HR 1.4, p = 0.0291), preoperative cerebrovascular accident (HR 1.8, p = 0.0367), preoperative endocarditis (HR 2.9, p = 0.0038) and chronic obstructive pulmonary disease (HR 1.9, p = 0.0287).
There were 19 cases of SVD, 16 managed by reoperation. The mean time to explant for SVD was 94.0 months (7.8 years; range 55.0-143.6 months). The overall freedom from SVD at explant was 85.6 AE 3.8% at 10 years (Table 4 ). Weibull analysis showed that the hazard function for SVD was increasing. Multi-decrement analysis illustrated that the cumulative incidence of SVD was 5.5 AE 1.3% at 10 years for an actual freedom from SVD of 94.5 AE 1.3%.
The freedom from SVD at explant based on the same age groups used for the illustration of patient survival (Fig. 1) was marginal ( p = 0.081). The actual (cumulative incidence) and actuarial freedom at 10 years, respectively, were 50-69 years 97.6 AE 2.3% (95.8 AE 4.1%), 70-79 years 91.3 AE 2.1% (78.5 AE 5.6%) and !80 years 100% (100%). The freedom from SVD at explant for patients !60 years was actual 94.4 AE 1.4% (actuarial 85.2 AE 3.9%; Fig. 2 ). For the age group !65 years, the freedom from SVD was similaractual 94.2 AE 1.4% (actuarial 85.0 AE 4.0%; Fig. 2 ). Fig. 3 shows the freedom for 61-70 years was actual 97.4 AE 2.6% (actuarial 95.7 AE 4.3%), and SVD freedom for >70 years was actual 94.0 AE 1.5% (actuarial 83.2 AE 4.6%) at 10 years.
Discussion
The Mitroflow pericardial bioprosthesis has been marketed worldwide, except in the United States, since 1982. In 1991, the cloth covering of this external mounted pericardial bioprosthesis was revised. It is this model that was approved for market in the United States in 2007. All publications on the prostheses either documented the clinical performance of the initial model or combined initial and current models [1] [2] [3] [4] [5] [6] [7] . This study was conducted to evaluate the clinical performance of the current model and, particularly, the durability at the mid term.
The Mitroflow bioprosthesis has been considered an ideal prosthesis for the small aortic root ( 19-21 mm). Yankah and co-authors [5, 6] The excellent haemodynamic performance has been further confirmed by Jamieson and Canadian colleagues [9] .
This clinical evaluation comprises the performance of the current model of the Mitroflow pericardial aortic bioprosthesis in 381 patients from two centres in Germany and one in Canada. The 10-year freedom from structural valve deterioration at explant (actual/actuarial) was: for !60 years 94.4% (85.2%); for !65 years 94.2% (85.0%); for 61-70 years 97.4% (95.7%); and for >70 years 94.0% (83.2%). The study also provided performance indicators of valve-related complications and composites of valve-related complications. There were no demonstrated adverse events that were above standard accepted criteria.
The evaluation of overall mortality revealed the independent predictors to be advanced NYHA class III/IV, coronary artery disease, pre-operative cerebrovascular accidents, pre-operative endocarditis, chronic obstructive pulmonary disease, age >80 years, left ventricular dysfunction (ejection fraction <35%) and moderate-to-severe PPM. There was a trend to moderate-to-severe effective orifice area indices influencing survival when the considered pEOAI level was <0.75 cm 2 m À2 . The review of the controversial topic of PPM is certainly beyond the scope of this documentation.
Pibarot and Dumesnil [16] proposed that PPM can be avoided by calculating preoperative EOAI from reference EOAs for the implanted valve. In our study, projected EOAI based on reference EOAs for the Mitroflow valve predicted that 12.2% of the patients would have moderate or severe PPM. Most of those were attributed to small valves placed in obese patients. We consider this level of PPM to be low, especially when considering the fact that most of the patients were implanted prior to establishment of the concept of using reference EOAs to determine the optimum valve size for a specific patient.
The summary of reported freedom from structural valve deterioration of pericardial and porcine bioprostheses is provided in Table 5 [3] [4] [5] [6] 10, [21] [22] [23] [24] [25] . The summary denotes whether SVD was considered only at reoperation or inclusive of clinical evaluation, including echocardiography.
The prior documentation of the Mitroflow bioprosthesis has been relatively confirmatory. The experience with earlier model of the prosthesis from Vancouver, Montreal, Victoria and Barcelona was reported on 1995, 1998 and 2008 [1, 2, 7] .
The 15-year experience reported by Benhameid and coauthors [7] revealed that actual/actuarial freedom from structural valve deterioration for 60-69 years was 73.9% (62.0%) and !70 years 91.4% (80.9%).
In 2005, Minami et al. [3] reported on 1512 aortic valve replacements of combined, previous and current models. The 15-year actuarial freedom from SVD was 63.4% in the populations with a mean age of 75.6 years. The authors graphically demonstrated 5-year subsets for SVD, concluding good durability in patients 75 years of age and older. In a published commentary, Bach suggested significant attrition at 5 years in patients 75-84 years and high rates of SVD in those less than 75 years [3] . It is obvious from several reports of heterograft durability that SVD does commence at 5-6 years. This is illustrated by Jamieson and co-authors [10] with the CE-SAV porcine aortic bioprosthesis, while the 15-18-year durability is equivalent to any long-term reported aortic Table 5 Summary of reported results from structural valve deterioration of pericardial and porcine bioprostheses. [3] with insufficiency present in 40% of SVDs. In 2008, Yankah et al. [6] reported, at 20 years, the actuarial freedom from reoperation for SVD in patients aged !65 and !70 years was 71.8% (actual 92.6%) and 84.8% (actual 96.6%), respectively.
The only other aortic pericardial bioprosthesis with extensive implantation is the Carpentier-Edwards PERI-MOUNT bioprosthesis, but the reported and marketed evidence is based on the original regulatory cohort of 267 patients, which has continuing follow-up but reported documentation beyond the report of Frater and co-investigators [21] at 14 years. Aupart et al. [22] has reported aortic actuarial freedom from SVD at 18 years of 77% for 60-70 years and 99% for >70 years. The predominant pathophysiology is dystrophic calcification with stenosis in 79% and tears and insufficiency in 21% [22] . Roselli and co-authors [25] also evaluated pathological features, including 267 patients from the original regulatory cohort and 211 from their own centre, identifying a distribution of pathology somewhat different from that of Aupart et al. [22] , relatively equal distribution of calcification and non-calcific degeneration with insufficiency.
The aortic porcine bioprostheses have very comparable results to the pericardial bioprostheses [21, 22] . Reported comparisons of the CE-SAV with the CE-PERIMOUNT and again with the Hancock II have not demonstrated differentiating features [10, [21] [22] [23] . The actuarial result of the St. Jude Medical Biocor is the longest standing report at 20 years with similar results [24] .
The limitations of this article are particularly related to the amalgamation of data from three centres where there may have existed selection biases in the choice of prostheses. The age criterion for the selection of this bioprosthesis was, in all likelihood, changing over time at the three centres. The method of evaluation is considered to be similar at the three centres, inclusive of primary physician contact, review of hospital and health records, structured interviews and/or structured mail questionnaires by telephone and mail, and clinic visitations with the accompaniment of echocardiograms, where considered appropriate by the attending physicians.
The Mitroflow pericardial bioprosthesis, with demonstrated excellent haemodynamic performance for the small aortic annulus, has very acceptable durability, at 10 years, for patients !60 years.
